KOREA study (Korea Osimertinib Real world Evidence study to Assess safety and efficacy) - KOREA
Study identifier:D5160R00009
ClinicalTrials.gov identifier:NCT02777567
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy
Medical condition
Non-small Cell Lung Cancer
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
315
Study type
Observational
Age
N/A
Date
Study Start Date: 29 Sept 2016
Primary Completion Date: 19 Mar 2020
Study Completion Date: 19 Mar 2020
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Sept 2020 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
